Mike Snape is an expert in the preclinical to clinical translational arena for neuroscience. To date, Dr. Snape has innovated and led multiple translational programs: developing AMO-02 (tideglusib) from preclinical efficacy screening to clinical proof of concept in neuromuscular disease, trofinetide from preclinical efficacy screening to clinical proof of concept in Rett Syndrome and AMO-01 (Diazepinomicin) from preclinical efficacy screening to clinical proof of concept in Phelan-McDermid Syndrome. Dr. Snape has extensive experience in designing, interpreting and overseeing preclinical efficacy experiments, with a focus on advancing the clinical readiness of various programs. To date, Dr Snape has raised approximately $120 million for the biopharma companies he has founded.